Delavirdine
Delavirdine Uses, Dosage, Side Effects, Food Interaction and all others data.
A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.
Delavirdine is a non-nucleoside reverse transcriptase inhibitor (nNRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Delavirdine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of Delavirdine does not compete with template or nucleoside triphosphates. HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases alpha, beta, or sigma) are not inhibited by Delavirdine.
| Trade Name | Delavirdine |
| Availability | Discontinued |
| Generic | Delavirdine |
| Delavirdine Other Names | Delavirdin, Delavirdina, Delavirdine, Delavirdinum |
| Related Drugs | Biktarvy, Truvada, tenofovir, ritonavir, Complera, Atripla, Stribild |
| Type | Oral |
| Formula | C22H28N6O3S |
| Weight | Average: 456.561 Monoisotopic: 456.194359482 |
| Protein binding | 98% |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | United States |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Delavirdine is a non-nucleoside reverse transcriptase inhibitor used to treat HIV infection.
For the treatment of HIV-1 infection in combination with appropriate antiretroviral agents when therapy is warranted
Delavirdine is also used to associated treatment for these conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection
How Delavirdine works
Delavirdine binds directly to viral reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by disrupting the enzyme's catalytic site.
Toxicity
Major toxicity of delavirdine is rash and should be advised to promptly notify their physician should rash occur. The majority of rashes associated with delavirdine occur within 1 to 3 weeks after initiating treatment with delavirdine. The rash normally resolves in 3 to 14 days and may be treated symptomatically while therapy with delavirdine is continued. Any patient experiencing severe rash or rash accompanied by symptoms such as fever, blistering, oral lesions, conjunctivitis, swelling, muscle or joint aches should discontinue medication and consult a physician.
Food Interaction
- Take with or without food. The absorption is unaffected by food.
Delavirdine Drug Interaction
Moderate: esomeprazole, esomeprazole, ritonavir, ritonavirUnknown: lactobacillus acidophilus, lactobacillus acidophilus, nitazoxanide, nitazoxanide, dicyclomine, dicyclomine, lamivudine, lamivudine, crofelemer, crofelemer, enfuvirtide, enfuvirtide, raltegravir, raltegravir, atropine / diphenoxylate, atropine / diphenoxylate
Delavirdine Disease Interaction
Elimination Route
Rapidly absorbed
Half Life
5.8 hours
Elimination Route
Delavirdine is extensively converted to several inactive metabolites by cytochrome P450 3A (CYP3A). Delavirdine was excreted in the milk of lactating rats at a concentration three to five times that of rat plasma.
Innovators Monograph
You find simplified version here Delavirdine
